Literature DB >> 15729526

Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.

Markus Frings1, Gerald Antoch, Philipp Knorn, Lutz Freudenberg, Ulrich Bier, Dagmar Timmann, Matthias Maschke.   

Abstract

In patients with anti-Yo associated paraneoplastic cerebellar degeneration (PCD) neurological symptoms precede the diagnosis of the underlying cancer in about 60%. Ovarian carcinoma, breast cancer and other gynaecological malignancies are most frequently found as causative malignancies. Antitumour treatment should be applied in an early stage of disease. The identification of the tumour is a diagnostic challenge in many of these patients. In the first of two patients reported here a pelvic tumour was suggested after detection of a pathological lymph node and elevated tumour markers. The intraoperative findings appeared macroscopically normal during ovariectomy with adnexectomy. Not until microscopic examination of the resected tissue was performed was a tubal adenocarcinoma found. If intrapelvic gynaecological tumours are suspected a deliberate surgical exploration seems to be justified, but only after an intensive diagnostic investigation. To search for the underlying cancer in patients with paraneoplastic neurological disorders successive CT and [18F]-FDG-PET are widely recommended. Instead of this in the second reported patient whole-body dual-modality PET/CT was performed revealing enhanced uptake in three regions of the left thorax. By combining function and anatomy PET/CT was able to localise the lesions and characterise them as lymph node metastases of breast cancer. Diagnosis could be confirmed by subsequently executed needle biopsy. PET/CT seems to be highly applicable in the investigation of paraneoplastic disorders with unknown primary cancer. It may help in guidance of needle biopsy or to optimise the results of deliberate surgery and it provides whole-body tumour staging in a single session with higher diagnostic accuracy than PET alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729526     DOI: 10.1007/s00415-005-0635-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Detection of primary tumor in paraneoplastic cerebellar degeneration by FDG-PET.

Authors:  Y Shinohara; Y Ohnuki; F Yoshii; W Takahashi; K Onoe; S Takagi
Journal:  Ann Neurol       Date:  1998-05       Impact factor: 10.422

2.  Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.

Authors:  I Rojas; F Graus; F Keime-Guibert; R Reñé; J Y Delattre; J M Ramón; J Dalmau; J B Posner
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

3.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

Authors:  P Trouillas; T Takayanagi; M Hallett; R D Currier; S H Subramony; K Wessel; A Bryer; H C Diener; S Massaquoi; C M Gomez; P Coutinho; M Ben Hamida; G Campanella; A Filla; L Schut; D Timann; J Honnorat; N Nighoghossian; B Manyam
Journal:  J Neurol Sci       Date:  1997-02-12       Impact factor: 3.181

4.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 5.  Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy.

Authors:  Raymond Voltz
Journal:  Lancet Neurol       Date:  2002-09       Impact factor: 44.182

6.  Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.

Authors:  U Berner; C Menzel; D Rinne; S Kriener; N Hamscho; N Döbert; M Diehl; R Kaufmann; F Grünwald
Journal:  Q J Nucl Med       Date:  2003-06

7.  Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients.

Authors:  K Peterson; M K Rosenblum; H Kotanides; J B Posner
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

8.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

9.  Paraneoplastic cerebellar degeneration: clinical-immunological correlations.

Authors:  N E Anderson; M K Rosenblum; J B Posner
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

Review 10.  Anti-tumour therapy in paraneoplastic neurological disease.

Authors:  W Grisold; M Drlicek; U Liszka-Setinek; E Wondrusch
Journal:  Clin Neurol Neurosurg       Date:  1995-02       Impact factor: 1.876

View more
  7 in total

1.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

2.  18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.

Authors:  Peter Bannas; Christoph Weber; Thorsten Derlin; Jörg Lambert; Frank Leypoldt; Gerhard Adam; Janos Mester; Susanne Klutmann
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

Review 3.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

4.  Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.

Authors:  N Schramm; A Rominger; C Schmidt; J N Morelli; C Schmid-Tannwald; F G Meinel; M F Reiser; C Rist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-16       Impact factor: 9.236

5.  Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Rebecca C Shay; Jennifer R Diamond; Jodi A Kagihara; Sharon B Sams
Journal:  J Breast Cancer       Date:  2021-02       Impact factor: 3.588

Review 6.  Cell-mediated immune responses in paraneoplastic neurological syndromes.

Authors:  Mikolaj Piotr Zaborowski; Slawomir Michalak
Journal:  Clin Dev Immunol       Date:  2013-12-30

Review 7.  Paraneoplastic neurological syndromes associated with ovarian tumors.

Authors:  Mikolaj Piotr Zaborowski; Marek Spaczynski; Ewa Nowak-Markwitz; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.